News

Results of Cancer Drugs Fund’s list reassessment announced

The results of a reassessment of the nationally approved list of drugs made available through the Cancer Drugs Fund (CDF) have been announced by NHS England. They confirm that Imnovid® (pomalidomide) for relapsed and refractory myeloma patients; Revlimid as a second-line treatment, and Velcade® as treatment for multiply relapsed Velcade-naive patients will remain on the list whereas…

Details

Updated UK guideline for the diagnosis and management of myeloma

The British Committee for Standards in Haematology (BCSH) and the United Kingdom Myeloma Forum (UKMF) Guideline for the Diagnosis and Management of Myeloma has recently been updated. Originally published in 2011, the latest changes to the guideline include the following recommendations: cytogenetic analysis should be performed in all patients at diagnosis; a second autologous stem…

Details